Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - Yahoo Finance

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential  Yahoo Finance

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - Yahoo Finance

Click here to get full coverage on Lexicon Pharma Leadership Takes Stage at Exclusive Jefferies Healthcare Conference - Stock Titan

Lexicon Pharma Leadership Takes Stage at Exclusive Jefferies Healthcare Conference  Stock Titan

Lexicon Pharma Leadership Takes Stage at Exclusive Jefferies Healthcare Conference - Stock Titan

Click here to get full coverage on Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%  simplywall.st

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates  Nasdaq

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider

Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851  StreetInsider

Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider

Click here to get full coverage on HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)  MarketBeat

HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Click here to get full coverage on Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension  TipRanks

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha

Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:LXRX)  Seeking Alpha

Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha

Click here to get full coverage on Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...  Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

Click here to get full coverage on Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial - Stock Titan

Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial  Stock Titan

Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial - Stock Titan

Click here to get full coverage on Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts  simplywall.st

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

Click here to get full coverage on LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - Yahoo Finance

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?  Yahoo Finance

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - Yahoo Finance

Click here to get full coverage on Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13  Stock Titan

Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

Click here to get full coverage on Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates  simplywall.st

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

Click here to get full coverage on Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal  Stock Titan

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Click here to get full coverage on Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Yahoo Finance

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10  Yahoo Finance

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Yahoo Finance

Click here to get full coverage on Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m - simplywall.st

Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m  simplywall.st

Private equity firms who have a significant stake must be disappointed along with institutions after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap dropped by US$148m - simplywall.st

Click here to get full coverage on First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment - Stock Titan

First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment  Stock Titan

First-Ever Phase 3 Trial Targets Both Forms of HCM: Lexicon's 500-Patient Global Study Could Transform Treatment - Stock Titan

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates  Yahoo Finance

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan

Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients  Stock Titan

Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus

Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News  GuruFocus

Lexicon Pharmaceuticals (LXRX) Receives Buy Rating from HC Wainwright & Co. | LXRX Stock News - GuruFocus

Click here to get full coverage on Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - Stock Titan

Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future?  Stock Titan

Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - Stock Titan

Click here to get full coverage on H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX) - StreetInsider

H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)  StreetInsider

H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX) - StreetInsider

Click here to get full coverage on Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...  Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Click here to get full coverage on Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Lexicon Pharmaceuticals faces potential Nasdaq delisting  Investing.com

Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Click here to get full coverage on Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - Stock Titan

Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista  Stock Titan

Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - Stock Titan

Click here to get full coverage on Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - Stock Titan

Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming  Stock Titan

Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming - Stock Titan

Click here to get full coverage on Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider

Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study  StreetInsider

Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? - Yahoo Finance

Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?  Yahoo Finance

Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? - Yahoo Finance

Click here to get full coverage on Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)  Seeking Alpha

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Click here to get full coverage on The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU

The Woodlands-based company strikes obesity-drug license deal worth up to $1B  KHOU

The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU

Click here to get full coverage on Lexicon: Q1 Earnings Snapshot - Stamford Advocate

Lexicon: Q1 Earnings Snapshot  Stamford Advocate

Lexicon: Q1 Earnings Snapshot - Stamford Advocate

Click here to get full coverage on Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com  Investing.com

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript  Insider Monkey

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga

Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?  Benzinga

Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On? - Benzinga

Click here to get full coverage on Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha

Lexicon stock rises on Novo Nordisk licensing deal (LXRX)  Seeking Alpha

Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha

Click here to get full coverage on What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Nasdaq

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals  Nasdaq

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Nasdaq

Click here to get full coverage on KURA Stock Rises More Than 15% This Past Week: Here's Why - TradingView

KURA Stock Rises More Than 15% This Past Week: Here's Why  TradingView

KURA Stock Rises More Than 15% This Past Week: Here's Why - TradingView

Click here to get full coverage on A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq

A Preview Of Lexicon Pharmaceuticals's Earnings  Nasdaq

A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq

Click here to get full coverage on Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista - Stock Titan

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista  Stock Titan

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista - Stock Titan

Click here to get full coverage on LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report  TradingView

LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Soars 4.70% on Positive Earnings - AInvest

Lexicon Pharmaceuticals (LXRX) Soars 4.70% on Positive Earnings  AInvest

Lexicon Pharmaceuticals (LXRX) Soars 4.70% on Positive Earnings - AInvest

Click here to get full coverage on Lexicon Pharmaceuticals jumps amid takeover speculation - MSN

Lexicon Pharmaceuticals jumps amid takeover speculation  MSN

Lexicon Pharmaceuticals jumps amid takeover speculation - MSN

Click here to get full coverage on Lexicon Pharmaceuticals receives additional compliance period from Nasdaq By Investing.com - Investing.com UK

Lexicon Pharmaceuticals receives additional compliance period from Nasdaq By Investing.com  Investing.com UK

Lexicon Pharmaceuticals receives additional compliance period from Nasdaq By Investing.com - Investing.com UK

Click here to get full coverage on Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive - openPR.com

Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive  openPR.com

Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive - openPR.com

Click here to get full coverage on H.C. Wainwright maintains $4 target on Lexicon shares - Investing.com

H.C. Wainwright maintains $4 target on Lexicon shares  Investing.com

H.C. Wainwright maintains $4 target on Lexicon shares - Investing.com

Click here to get full coverage on Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com

Lexicon Pharmaceuticals to present at Healthcare Conference  Investing.com

Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com

Click here to get full coverage on H.C. WAINWRIGHT MAINTAINS BUY RATING ON LEXICON STOCK, $4 TARGET - Investing.com

H.C. WAINWRIGHT MAINTAINS BUY RATING ON LEXICON STOCK, $4 TARGET  Investing.com

H.C. WAINWRIGHT MAINTAINS BUY RATING ON LEXICON STOCK, $4 TARGET - Investing.com

Click here to get full coverage on Lexicon Pharmaceuticals stock hits 52-week low at $0.37 - Investing.com

Lexicon Pharmaceuticals stock hits 52-week low at $0.37  Investing.com

Lexicon Pharmaceuticals stock hits 52-week low at $0.37 - Investing.com

Click here to get full coverage on Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - Yahoo Finance

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain  Yahoo Finance

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain - Yahoo Finance

Click here to get full coverage on Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com

Lexicon Pharmaceuticals stock tumbles after clinical study results  Investing.com

Lexicon Pharmaceuticals stock tumbles after clinical study results - Investing.com

Click here to get full coverage on Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - TradingView

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference  TradingView

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - TradingView

Click here to get full coverage on Lexicon stock plummets following Phase 2b study results - Investing.com

Lexicon stock plummets following Phase 2b study results  Investing.com

Lexicon stock plummets following Phase 2b study results - Investing.com

Click here to get full coverage on Lexicon Q1 2025 slides: EPS beat, revenue miss, strategic partnerships advance By Investing.com - Investing.com South Africa

Lexicon Q1 2025 slides: EPS beat, revenue miss, strategic partnerships advance By Investing.com  Investing.com South Africa

Lexicon Q1 2025 slides: EPS beat, revenue miss, strategic partnerships advance By Investing.com - Investing.com South Africa

Click here to get full coverage on LEXICON PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

LEXICON PHARMACEUTICALS, INC. SEC 10-K Report  TradingView

Lexicon Pharmaceuticals Inc (LXRX)

Price Chart

Key Statistics

Technicals

About LXRX

Latest News

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - Yahoo Finance

Lexicon Pharma Leadership Takes Stage at Exclusive Jefferies Healthcare Conference - Stock Titan

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st

Advanced Charts

Top Gainers

Top Losers